NewLimit ( @newlimit ) just raised an additional 45 million at a 1.62 billion valuation, and we're proud to continue backing this mission. When Big Pharma, a major university endowment, and top-tier VCs all double down at a 1.62B valuation, you're watching capital flow toward breakthrough science that's delivering results. Why we invested (again): This round was propelled by new technical breakthroughs following their Series B that set the stage for their first clinical study in a few years. Technical breakthroughs five months after a Series B? That's execution velocity that demands follow-on investment. NewLimit is developing medicines that can restore youthful function in old cells through epigenetic reprogramming. NewLimit believes that a new class of longevity medicines can improve the lives of everyone on the planet, even those not diagnosed with a classically defined disease. For decades, medicine has treated disease after it manifests. NewLimit targets the underlying aging process itself before disease emerges. Longevity isn't a niche market. Everyone ages. Every cell accumulates damage over time. Science is advancing faster than expected. The capital is flowing to the right companies. The clinical timelines are getting real. NewLimit is proving that epigenetic reprogramming isn't science fiction, it's the next frontier of medicine.(Tim Draper)